newsfilter
← Latest News
PR Newswire·

TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

  • Faruqi & Faruqi, LLP is investigating potential securities claims against Tvardi Therapeutics, Inc. (NASDAQ: TVRD).
  • On October 13, 2025, Tvardi shares plummeted over 80% following disappointing preliminary data from the Phase 2 REVERT clinical trial of TTI-101 for idiopathic pulmonary fibrosis.
  • The study assessed safety, pharmacokinetics, & exploratory outcomes related to lung function but concluded it did not meet its goals.
  • Preliminary data showed baseline characteristics were similar across treatment arms except for percent predicted FVC, which was lower in placebo-treated patients compared to TTI-101-treated arms.
  • Senior Partner James (Josh) Wilson encourages investors with significant losses to contact him at 877-247-4292 or 212-983-9330 (Ext. 1310).
  • Additional information regarding the investigation is available at www.faruqilaw.com/TVRD.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.